Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

by admin January 23, 2025
January 23, 2025
Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

HCA Healthcare operates one of the most comprehensive hospital networks in the US, encompassing over 180 hospitals and approximately 2,400 sites of care in 20 states.

The national contract covering the deployment of Technegas in nuclear medicine departments across the entire HCA network was instigated by HCA after multiple of its sites entered into independent discussions with Cyclopharm regarding Technegas. This prompted HCA head office to initiate the creation of a broad-based contract which will bypass the need for individual site contract negotiations and most efficiently streamline the deployment of Technegas technology.

The agreement further underscores the commercial demand for Technegas which is already the preferred agent of choice in 65 countries outside the US for diagnosing lung conditions, including pulmonary embolism, hypertension, chronic obstructive pulmonary disease (COPD), and other respiratory diseases.

Cyclopharm CEO James McBrayer said, “We are thrilled to partner with HCA Healthcare, a leader in delivering quality care to millions of patients annually. This 3-year agreement will allow for the accelerated availability of Technegas across the US and reinforces our commitment to improving outcomes for patients with respiratory conditions.”

As well as streamlining implentation across up to 169 HCA nuclear medicine departments, today’s agreement opens discussions with the HealthTrust Purchasing Group (HealthTrust)2, HCA’s affiliated group purchasing organisation (GPO) that serves as the contracting and purchasing arm to a further network of over 1,800 hospitals in the USA.

Cyclopharm will now engage directly with individual HCA locations, clinical leaders and Divisional Directors to implement Technegas, prioritising those sites which had already entered preliminary discussions with Cyclopharm.

Technegas has been recognized globally for its ability to provide precise and reliable functional lung imaging. With this contract, HCA facilities will be at the forefront of adopting advanced nuclear medicine technology, ensuring better diagnostic and therapeutic options for their patients.

Mr. McBrayer concluded, “This agreement not only extends the footprint of Technegas in the US market but also sets the stage for its broader adoption within HealthTrust’s extensive network. We are proud to support HCA in its mission to provide exceptional care and are eager to see the positive impact of our technology on patients and clinicians alike.”

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
‘Moana 2’ tops $1 billion, extending Disney’s box office domination
next post
Eclipse Metals Ltd Progresses Grønnedal Resource Expansion: Analytical Assessment of Historical Drill Core Samples Underway

Related Posts

Rob McEwen: Gold to Hit US$5,000 Long Term,...

March 18, 2025

Alderan Receives Approval to Commence Drilling at New...

August 3, 2024

Sarama Resources Advances Mt Venn Gold Project Acquisition

February 27, 2025

Announcement by Cyclone Metals Ltd

November 22, 2024

Tech 5: Trump to Prioritize Crypto, Biden Blocks...

January 19, 2025

Maria Smirnova: Gold, Silver Price Drivers Still in...

February 4, 2025

ALX Resources

May 18, 2024

6 Mining Companies Make Top 20 on 2025...

January 18, 2025

Launch of Underwritten $24.3M Equity Raising

May 23, 2024

Tech 5: Bitcoin’s Price Sets Five New Records,...

November 23, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Strategic Chaos or Tactical Goldmine? What QQQ’s Chart is Whispering Right Now

      June 5, 2025
    • Why ADX Can Mislead You — And How to Avoid It

      June 5, 2025
    • S&P 500 on the Verge of 6,000: What’s at Stake?

      June 5, 2025
    • Speaker Johnson surprised by Musk’s criticism of ‘big, beautiful bill’: He’s ‘flat wrong’

      June 5, 2025
    • There’s a way to aid Gaza. I know, my foundation just helped deliver 7 million meals… without incident

      June 5, 2025

    Categories

    • Business (967)
    • Investing (2,320)
    • Politics (2,873)
    • Stocks (1,054)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved